Evotec SE (ETR:EVT) shares were down 0.4% during mid-day trading on Wednesday . The company traded as low as €34.41 ($40.48) and last traded at €34.69 ($40.81). Approximately 464,408 shares changed hands during trading, a decline of 66% from the average daily volume of 1,360,000 shares. The stock had previously closed at €34.83 ($40.98).
A number of equities analysts have issued reports on EVT shares. Royal Bank of Canada set a €39.00 ($45.88) price objective on shares of Evotec and gave the stock a “buy” rating in a report on Wednesday, May 19th. Deutsche Bank Aktiengesellschaft set a €33.00 ($38.82) price objective on shares of Evotec and gave the stock a “neutral” rating in a report on Wednesday, May 12th. Warburg Research set a €40.00 ($47.06) price objective on shares of Evotec and gave the stock a “buy” rating in a report on Friday, May 7th. Finally, Baader Bank set a €33.00 ($38.82) target price on Evotec and gave the stock a “buy” rating in a research note on Tuesday, May 11th.
The company has a quick ratio of 2.61, a current ratio of 2.84 and a debt-to-equity ratio of 65.20. The firm has a market cap of $5.75 billion and a P/E ratio of 130.53. The company has a 50 day simple moving average of €34.18.
Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services.
Featured Article: Moving Average Convergence Divergence (MACD)
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.